TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02804880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HAR
Description: Smokers will be introduced to various smoking cessation (SC) services in Hong Kong (using the referral card) and be motivated to use the services. Field research staff will assist on-site booking SC services for smokers. Tailored messages, including: harm of smoking, benefit of smoking cessation, importance of adherence to smoking cessation appointment and encouragement on abstinence will be sent via instant messaging (IM) services (e.g. WhatsApp, WeChat) to smokers after initial contact.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LTM
Description: Fix-schedule SMS messages will be sent to encourage them to book the smoking cessation services appointment. Smokers are required to book the SC appointments by themselves.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARD
Description: Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again: to repeat the intervention during tel. follow-ups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARD
Description: Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again: to repeat the intervention during tel. follow-ups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral card
Description: The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral card
Description: The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A4 leaflet
Description: The 2-side color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A4 leaflet
Description: The 2-side color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief advice
Description: Very brief, minimal and general smoking cessation advice

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 12-page booklet
Description: 12-page smoking cessation self-help booklet
Study: NCT02786589

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood-stage infection of P. vivax
Description: Each patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.3-1×10\^7 Plasmodium parasites.And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples.The treatment will last at least 12 weeks from the day of finding the Plasmodium from peripheral blood and will be terminated by chloroquine phosphate or Artemisinin compound preparation or Artesunate injection.
Study: NCT03572439

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Sensory block level check using ice
Description: Patients are asked to report when the ice feels as cold as it does on the forehead.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Sensory block level check using ice
Description: Patients are asked to report when the ice feels as cold as it does on the forehead.
Study: NCT02563288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Description: effect of esmolol on intraoperative sympathetic control and on extubation conditions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: effect of dexmedetomidine on intraoperative sympathetic control and on extubation conditions.
Study: NCT02197039

Intervention type: DRUG
Intervention: esomeprazole or pantoprazole
Description: Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis is achieved spontaneously or by gastroscopy. Patients then receive a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Because of concern for patient safety with certain drug-drug interactions, patients who take clopidogrel receive intravenous pantoprazole (Pantoloc®, Takeda, Singen, Germany), including an 80 mg loading dose and a 3-day continuous high-dose (8 mg/h) of infusion.

Intervention type: DRUG
Intervention: esomeprazole or pantoprazole
Description: Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis is achieved spontaneously or by gastroscopy. Patients then receive a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Because of concern for patient safety with certain drug-drug interactions, patients who take clopidogrel receive intravenous pantoprazole (Pantoloc®, Takeda, Singen, Germany), including an 80 mg loading dose and a 3-day continuous high-dose (8 mg/h) of infusion.

Intervention type: PROCEDURE
Intervention: Endoscopic hemostasis
Description: At the index gastroscopy, bleeding ulcers are checked. If the adherent clot is found over the ulcer base, it will be vigorously washed away with water jet. All of the stigmata of recent hemorrhage (SRH) are treated by one or a combination of endoscopic therapies including local injection of diluted epinephrine 1:10000, bipolar heated probe at 20 J per goal consecutively until achievement of coaptive coagulation, argon plasma coagulation, band ligation, or hemoclip therapy. The success of endoscopic hemostasis is defined as cessation of bleeding together with achievement of cavitation at the vessel after application of the heater probe.

Intervention type: PROCEDURE
Intervention: Endoscopic hemostasis
Description: At the index gastroscopy, bleeding ulcers are checked. If the adherent clot is found over the ulcer base, it will be vigorously washed away with water jet. All of the stigmata of recent hemorrhage (SRH) are treated by one or a combination of endoscopic therapies including local injection of diluted epinephrine 1:10000, bipolar heated probe at 20 J per goal consecutively until achievement of coaptive coagulation, argon plasma coagulation, band ligation, or hemoclip therapy. The success of endoscopic hemostasis is defined as cessation of bleeding together with achievement of cavitation at the vessel after application of the heater probe.
Study: NCT01205672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 850 mg by mouth once daily for at least 7 days, and up to 30 days before surgery.
Study: NCT03272945

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Linked-color imaging
Description: Linked-color imaging colonoscopy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Linked-color imaging
Description: Linked-color imaging colonoscopy
Study: NCT03121222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: The antioxidant group received orally two N-acetylcysteine tablets (each tablet contained 600 mg of NAC; Lamberts Health Care Ltd, Kent, United Kingdom). The participants were instructed to receive the capsules every twelve hours in order to achieve high concentration of N-acetylcysteine throughout the 24 h. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption. The supplementation period was 30-day for N-acetylcysteine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose
Description: The placebo group received orally two lactose tablets per day. The participants were instructed to receive the capsules every twelve hours. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption. The supplementation period was 30-day for placebo.
Study: NCT03007953

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative Care
Description: Care delivered by a nurse, including symptom assessment and management, patient education on lung cancer and treatment options, discussion and communication about preferences for care, psychosocial assessment (including referrals to ancillary services), and patient-centered resources. A personalized treatment plan based on the patient's lung cancer stage, treatment, symptoms and psychosocial needs will be developed by the palliative care team (physician, study nurse) with input from the patient and family member. The study nurse will assess patient's symptoms, implement and monitor the treatment plan applying established End-of- Life Nursing Education Consortium (ELNEC) for Veterans protocols.
Study: NCT02123160

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Parent Psychotherapy (CPP)
Description: Child Parent Psychotherapy (CPP) is a multi-theoretical approach to enhance the caregiver-child relationship in the context of the caregiver's psychiatric history (e.g., depression) and/or caregiver/child exposure to traumatic events. Mother and child's in-session interactions are used to provide developmental guidance, and reinforce reciprocity between parent and child, affect regulation , continuity in daily living, and helping mother and child understand themselves and each other in the context of the maternal psychiatric functioning and/or familial exposure to trauma. When there is a history of trauma exposure for mother and/or child, mother and child create a joint narrative of the trauma, identify and address traumatic triggers, and focus on safety issues.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control (usual treatment)
Description: Following Time 1 (pre-treatment) assessment, mother-child patient dyads randomized to the control group will be referred to usual treatment in the community for psychoeducation, counseling/ therapy for maternal depressive symptoms, and child behavioral/ emotional difficulties. Control patient dyads will be closely monitored through regular contact with the study research assistant and follow up by a licensed study clinician to assess mother/ child's psychiatric functioning and make necessary referrals to alternative treatments or arrange an emergency evaluation, if needed.
Study: NCT02898207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onalespib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onalespib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onalespib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onalespib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onalespib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onalespib
Description: Given IV
Study: NCT01449591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFH772 1% ointment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle ointment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Noritate® 1% cream
Study: NCT00626912

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endovascular coil embolization
Description: standard endovascular coil embolization with or without adjunct techniques

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endovascular coil embolization
Description: standard endovascular coil embolization with or without adjunct techniques
Study: NCT01425073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinue TMP/SMZ prophylaxis
Description: Subjects in the intervention arm will discontinue use of daily TMP/SMZ for the duration of the study
Study: NCT03563703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound allows viewing veins and surrounding anatomical structures, making it easier to perform the placement of a cannula into a peripherally located vein in real time. This process allows the cannulation of veins that are unable to be visualised or palpated.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near Infrared Light
Description: Infrared technologies allows illuminating the vein with a near-infrared light, which is absorbed by blood and reflected by adjacent tissue.
Study: NCT00905021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane 25 mg by mouth every day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sutent
Description: Sunitinib 37.5 mg by mouth every day.
Study: NCT01806246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: integrative rehabilitation program
Study: NCT04393636

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital cardiac Counseling
Description: * Screening for reduced physical fitness and digital counseling.~* Screening for smoking and digital counseling.~* Screening for malnutrition and obesity and digital counseling.~* Screening for anxiety and depression and digital counseling.~* Screening for elevated pulmonary risk score and digital counseling.
Study: NCT01680588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]NAV4694
Study: NCT03664622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine group to whom intravenous ketamine was administered in a loading dose of 0.15 mg/kg over 5 min, 10 minutes pre incision, followed-by an infusion at 2 micg/kg/min until the end of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: a loading dose of 0.1 mg/kg over 20 min intravenously, 10 minutes pre incision, then infused with morphine an infusion rate of 5 - 40 microgram/kg/hour till the end of surgery.
Study: NCT00327665

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 11-valent pneumococcal vaccine GSK513026
Description: Two-dose intramuscular injection. Each group receiving one of the 3 formulations

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 11-valent pneumococcal vaccine GSK513026
Description: Two-dose intramuscular injection. Each group receiving one of the 3 formulations

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumo 23™
Description: Single-dose intramuscular injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 1 intramuscular injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 10-valent pneumococcal vaccine GSK513026
Description: Two-dose intramuscular injection
Study: NCT02843295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples
Study: NCT04802850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan mobilization with movement
Study: NCT03467555

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Class II correction using miniplates in zygomatic region
Study: NCT01967654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technical Assistance, training and clinical reminders

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral to Community Health Worker
Study: NCT02176096

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glycosade
Study: NCT04076202

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cementless Vanguard DD RP
Description: Patients treated with the Cementless Vanguard DD RP knee implant
Study: NCT02618278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: The aims of physiotherapy are to promote physical and psychological health for the patient, and in doing so promote and improve function. In light of the evidence to suggest spontaneous resorption of the disc fragment occurs, physiotherapy provides support and guidance for the patient to manage their symptoms whilst resorption takes place. The physiotherapy regimen will be tailored to the individuals' requirements. It will be goal orientated, and assessed using a biopsychosocial approach based on 7 different elements; neurological dysfunction, motor control of movement of the lumbar spine and pelvis, movement restriction in the lumbar spine and pelvis, psychological barriers to recovery, advice and education, functional-based exercise and pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: The aims of physiotherapy are to promote physical and psychological health for the patient, and in doing so promote and improve function. In light of the evidence to suggest spontaneous resorption of the disc fragment occurs, physiotherapy provides support and guidance for the patient to manage their symptoms whilst resorption takes place. The physiotherapy regimen will be tailored to the individuals' requirements. It will be goal orientated, and assessed using a biopsychosocial approach based on 7 different elements; neurological dysfunction, motor control of movement of the lumbar spine and pelvis, movement restriction in the lumbar spine and pelvis, psychological barriers to recovery, advice and education, functional-based exercise and pain.
Study: NCT01421654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: S9 Elite with Acclimate
Description: S9 Elite Flow Generator with Acclimate feature activated

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: S9 Elite
Description: S9 Elite Flow Generator
Study: NCT00299741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 50 mg daily, 4/2 schedule
Study: NCT04336540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu configuration (presence of energy labelling)
Description: Restaurant menus are altered to accommodate energy labelling intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu configuration (presence of energy labelling)
Description: Restaurant menus are altered to accommodate energy labelling intervention
Study: NCT04802850

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Mulligan mobilization with movement
Study: NCT00586924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxetumomab Pasudotox (CAT 8015)
Description: Participants received intravenous infusion of 5 microgram per kilogram (mcg/kg) moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until complete response (CR), progressive disease (PD), initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
Study: NCT04336540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu configuration (more lower energy options added)
Description: Restaurant menus are altered to include more lower energy options
Study: NCT01671124

Intervention type: OTHER
Intervention: Soline capsule
Study: NCT04157530

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: wang-bu-liu-xing
Description: wang-bu-liu-xing applied on the surface of Jinming and Qiuhou acupoints

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture applied to Qingming and Qiuhou with Der-qi

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: acupuncture, but the needles of Qinming and Qiuhou connected to the electroacupuncture machine after Der-qi, the frequencies of stimulus were 6 Hz, the intensity of stimulus was minimal visible muscle twitch
Study: NCT00628719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Amphotericin B
Description: a single dose of 10 mg/kg of liposomal amphotericin B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amphotericin B deoxycholate
Description: amphotericin B as a 1x test dose and then at a dose of 1 mg/kg/every other day for a total of 15 doses over 30 days.
Study: NCT00586924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxetumomab Pasudotox (CAT 8015)
Description: Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxetumomab Pasudotox (CAT 8015)
Description: Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxetumomab Pasudotox (CAT 8015)
Description: Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT 8015 (Moxetumomab Pasudotox)
Description: Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxetumomab Pasudotox (CAT 8015)
Description: Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
Study: NCT01249183

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Concomitant administration
Description: 1 dose (0.5 mL) of VAXIGRIP and 1 dose (0.5 mL) of REPEVAX in 2 separate injections sites (1 on each arm)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Separate administration
Description: 1 dose (0.5 mL) of VAXIGRIP at Day 0 and 1 dose (0.5 mL) of REPEVAX 28 days later